Strategy

Online pharmacies are touting more than just Viagra. Here's what pharma is hoping to do about it

AstraZeneca is releasing 1,400 employees in Europe, and refocusing its packing system in an effort to move product closer to where the demand is. In this case, that's China.

Significant and dramatic healthcare policy changes are likely to follow after Barack Obama takes the oath of office and the expanded Democratic congressional majority settles in. But what does the electoral outcome mean for healthcare companies and the industry as a whole?

AstraZeneca caused a ruckus at the American Heart Association's annual meeting as data was released proving that its statin not only works for its target indication, but also reduced major CV events in patients who don?t have high cholesterol.

A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri

The former health secretary offers a reality check on healthcare reform-and what to expect from the pols in '09

Here are the hottest gadgets and gizmos to make a dent in drug noncompliance

Some say it's just another pharma facing its patent cliff. But others say this company's got it worse. With new CEO John Lechleiter in charge, can Lilly find its way back from the edge?

Industry is cinching its belt, but news that Merck will shed 12 percent of its workforce - many senior and middle management positions - was a bombshell announcement.

New legislation gives US-based Web hosting companies the go-ahead to remove shady online pharmacies without a warrant. The new rule makes it harder to market counterfeit drugs, and for consumers to purchase medication without a prescription.

Novartis is the latest pharma company to move away from the traditional sales model of blanketing sales reps for one drug across the nation. The company is restructuring its force (and cutting jobs) to focus on a regional sales model.

Specialty drug firm Norgine splits from the British pharma association due to a growing rift about pricing. A "war of the roses" is escalating between Big Pharma and smaller drug manufacturers; Norgine could be the first casualty.

The pharma giant just announced major plans to break up its R&D divisions into smaller units targeting areas of growth. Marketing will be part of the restructuring plan, and there is good news: No new layoffs.

Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.

Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?

Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.

Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit.

A new study from the NIMH shows that next-generation treatments for schizophrenia might not be any better than older, first generation drugs-and in some cases might be worst.

A new study shows that while the combo drug decreases the chance of coronary artery disease, it doesn't work as well in slowing down aortic valve disease. So why is all the focus on cancer deaths?

The Belgium-based drug maker is terminating 2,000 jobs and rebranding itself as a biopharm with a focus on CNS and immunology drugs. Pharm Exec gave UCB a call to find out more.

Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)

Outsourcing saves money-except when it doesn't. Here's how to decide what to do.

The case for preemption gets shot down in Texas, but holds up in yet another Medtronic suit in Minnesota.

Margaret McGlynn, Merck's head of vaccines, expounded yesterday on the state of the company's vaccine program, including campaign strategies, product development, and a new reimbursement program for doctors.

A new study reports that more than 27 percent of Americans are not being treated for HIV because they fear adverse reactions to the drugs. Pharm Exec talked to the doctors in charge of the survey to learn more.